Cabazitaxel/(CAS 183133-96-2)/Anticancer Cabazitaxel 

Cabazitaxel (CAS 183133-96-2) is a highly effective taxane antineoplastic agent, with its core mechanism of action being promoting tubulin polymerization and stabilizing microtubule structures. It blocks the mitotic process of tumor cells, ultimately inducing tumor cell apoptosis, and has unique inhibitory activity against drug-resistant prostate cancer and other solid tumors.

Its high-purity chemical properties ensure the stability and reproducibility of pharmacological effects, while it also has favorable lipophilicity, enabling efficient penetration of tumor cell membranes and increasing drug enrichment concentration at tumor sites. This product is suitable for the clinical treatment of castration-resistant prostate cancer, especially with key therapeutic value for docetaxel-resistant cases. Meanwhile, it is also an excellent experimental sample for pharmaceutical companies to develop taxane antineoplastic drugs and scientific research institutions to explore tumor cell cycle regulation mechanisms, meeting the dual needs of clinical treatment and scientific research.